Palantir stake in SRFM increased to 18.5% – A Future $75B Market Opportunity Just Got Even More Interesting… (MicroCapWatch)
Insiders are Betting Millions on these Hot Stocks
If insiders are putting their money where their mouths are, dig into it.
After all, it’s the insiders that know their company the best. And if they’re buying, there’s usually a good reason for it.
Look at Southwest Airlines (LUV), for example.
Director Rakesh Gangwal just bought 3.6 million shares of the airline stock for about $108 million. He was added to the LUV board in July following Elliott Investment Management’s push for new leadership and strategic changes.
As part of the overhaul, it was announced that executive chair Gary Kelly would be stepping down, and that six other board members would also be stepping down as well.
And, as noted by Investing.com:
“Despite these significant changes, Elliott continues to call for further adjustments, including the removal of CEO Bob Jordan. Last week, Elliott signaled its intent to request a special shareholder meeting to push for additional leadership changes.”
“In an interview with Reuters, Gangwal expressed concerns about further disruptions in Southwest’s leadership, stating that more changes would be ‘counterproductive’ and detrimental to shareholders. He stressed that beyond the steps already announced, additional alterations to the board or executive team would not be in the best interest of shareholders.”
Cantaloupe (CTLP)
Cantaloupe, a digital payments and software services company, just saw Chairman Douglas Bergeron buy another 285,000 shares of the stock.
Even CEO Ravi Venkatesan picked up another 8,000 shares of the stock, noting that, “I have never been more confident of our market position and our growth vectors. These investments by both Bergeron and myself signal our belief in the company’s strategic direction and growth potential,” as quoted by Seeking Alpha.
Terns Pharmaceuticals (TERN)
The clinical-stage biopharmaceutical company owns a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity.
Fueling upside, the company just said TERN-601 for obesity was well tolerated and showed statistically significant mean weight loss across all three doses evaluated (240mg, 500mg, 740mg) in the 28-day multiple-ascending dose trial, with maximum placebo-adjusted mean weight loss of 4.9% (p<0.0001) at the highest dose of 740mg. Additionally, 67% of participants lost 5% or more of their baseline body weight at the top dose.”
Company director Hongbo Lu also bought 476,190 shares at a price of $10.50 per share, for nearly $5 million.
Related Reading: Fed Triggers Boom: Buy this Play on Elon’s New AI
Have you seen Elon Musk’s new invention?
I was already very bullish on this new type of AI.
And now that the Fed has just cut interest rates, I’m even more bullish.
By now, you know that the Fed just fired off their bazooka and cut interest rates by 0.5%.
The stock market is already making new all time highs.
And if history is any guide, it will likely keep moving higher.
You see, in the past 40 years, the Fed has cut rates 12 times with the S&P 500 within 1% of an all-time high.
The market was higher a year later ALL 12 times with an average return of around 15%.
So when you combine this Fed cut with this Elon Musk new type of AI…
I predict the result will be a massive boom.